SANTA BARBARA, CA--(Marketwire - September 29, 2010) - A new article, published this month in Diabetes Therapy, provides a comprehensive review of the OmniPod Insulin Management System (Insulet Corp., Bedford MA, USA) (NASDAQ: PODD) -- an automated, tube-free insulin pump that can be controlled wirelessly through a handheld device containing an integrated blood glucose meter. Written by Howard C. Zisser M.D., Director of Clinical Research and Diabetes Technology at Sansum Diabetes Research Institute, the article concludes that the OmniPod System improves upon existing conventional insulin delivery products and can benefit almost any patient with type 1 diabetes.
"For many patients with type 1 diabetes, continuous subcutaneous insulin infusion therapy is the only way to reach acceptable glucose control levels," said Dr. Zisser. "The OmniPod Insulin Management System improves upon conventional delivery systems by allowing precise, round-the-clock insulin management coupled with a convenient tube-free design and an intuitive user interface."
Unlike multiple daily injection (MDI) therapy, typically requiring four separate manually administered doses in a 24-hour period, the OmniPod Insulin Management System can provide uninterrupted and steady insulin delivery to patients.
Dr. Zisser also notes that the OmniPod Insulin Management System provides a number of advantages to the patient with respect to comfort and general ease of use. The device's handheld Personal Diabetes Manager (PDM) enables easier set-up and fully-automated cannula insertion. The watertight Pod also provides consistent, uninterrupted insulin delivery because patients do not need to disconnect for activities like bathing or swimming. These features, coupled with the ability to track daily, monthly, and quarterly progress may also help to empower patients and improve compliance.
Dr. Zisser also noted that a review of past clinical studies further validates the utility of the OmniPod Insulin Management System. Previous peer-reviewed publications have documented a statistically significant decrease in glycated hemoglobin levels (or A1C levels, used to determine average plasma glucose concentration over time), significantly less variation in insulin delivery compared to pumps with tubing in a laboratory environment, and a patient preference over conventional devices.
About Sansum Diabetes Research Institute
Sansum Diabetes Research Institute is a non-profit research center devoted to the prevention, treatment and cure of diabetes through research and education. In particular, it is known for its work on methods to detect and chart the progress of diabetes and its expertise in new diabetes technology.
About Insulet Corporation
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA.
About the OmniPod Insulin Management System
The OmniPod Insulin Management System is the world's first tubing-free insulin pump. OmniPod offers people living with insulin-requiring diabetes all the benefits of insulin pump therapy, with unprecedented freedom, comfort and ease. OmniPod has just two components: the small, discreet, watertight Pod, worn almost anywhere on the body to hold and deliver insulin; and the PDM (Personal Diabetes Manager), a hand-held device that communicates wirelessly to program the Pod, calculates suggested doses and has a built-in FreeStyle® blood glucose meter. For more information, please visit: www.myomnipod.com